phone 1 (579) 885-8988 email contact@exceleve.com

2nd Global Webinar on
Emerging Infectious Diseases

September 11, 12 2021
A Global Debate on Infectious Diseases: R&D, Therapeutics and Management

Home / Submission & Sessions

ABSTRACT SUBMISSION FORM

Call for Abstracts

  1. Coronavirus (COVID 19)
  2. Perioperative considerations for patients with COVID-19
  3. Future Epidemics: Prediction, Control and Prevention
  4. Borrelia mayonii (new in FY18)
  5.  Novel Trends in Emerging Diseases Management
  6.  Remdesivir in COVID-19  
  7. COVID-19 and Pregnancy
  8. Pandemic  COVID-19 and Ischemic Stroke
  9.  Investigational approaches for COVID-19 therapy  
  10. Clinical features of COVID-19 in children  
  11. Management of the intubated COVID-19 patient  
  12. Epidemiology and Infection
  13.  What's new in Infectious & Unprecedented diseases
  14. Epidemiology and Community Health
  15. Disease Control & Trends in Maternal Mortality
  16.  Primary care epidemiology, Paediatric epidemiology
  17.  FLU and Future Epidemic and Pandemic Diseases
  18.  Adaptive Immunity and Herd Immunity
  19.  Neurologic complications of severe COVID-19
  20.  BioEthics and Clinical Trials and Alternative Approaches
  21.  COVID 19 and Phylogenetic analysis
  22.  Therapeutic Strategies
  23.  Balamuthia mandrillaris (new in FY14)  Bartonella henselae, Bacillus anthracis 
  24.  BK virus, Bordetella pertussis (new in FY15)  
  25. Bunyaviruses  Burkholderia mallei (glanders)
  26.  Burkholderia mallei (glanders)  
  27. Burkholderia pseudomallei (melioidosis)  Caliciviruses
  28.  California encephalitis  
  29. Campylobacter jejuni  Category C Priority Pathogens
  30.  Chikungunya Virus  Chlamydia psittaci (Psittacosis)  
  31.  Coxiella burnetii (Q fever)  
  32. Cryptosporidium parvum  Cyclospora cayatanensis
  33.  Dengue  Diarrheagenic E.coli
  34.  Eastern equine encephalitis (EEE)  Ehrlichiosis
  35.  Entamoeba histolytica  
  36. Enterovirus 68 (new in FY15)  Enterovirus 71
  37.  Epsilon toxin (Clostridium perfringens)  
  38. European subtype  Far Eastern subtype  Food- and waterborne pathogens  
  39. Francisella tularensis (tularemia)
  40.  Fungi  Giardia lamblia  Hantaviruses causing Hanta Pulmonary syndrome
  41. Hepatitis E (new in FY14)  Human herpesvirus 6
  42.  Human herpesvirus 8  
  43. Immunological Studies
  44.  Immunology studies that advance our understanding of host defenses applicable to the biodefense effort  
  45. Influenza virus
  46.  Innate Immunity  
  47. Japanese encephalitis virus (JE)
  48.  JC virus (new in FY14)
  49.  Junin, Machupo, Guanarito, Chapare (new in fiscal year (FY14), Lassa, Lujo (new in FY14)
  50.  LaCrosse encephalitis (LACV)  Leptospirosis (new in FY14)
  51.  Listeria monocytogenes  Microsporidia  
  52. Mosquito-borne viruses  Mucormycosis (new in FY14)  Mucosal Immunity
  53.  Naegleria fowleri (new in FY14)  
  54. Naegleria fowleri (new in FY14)  Nipah and Hendra viruses  Omsk Hemorrhagic Fever virus, Alkhurma virus, Kyasanur Forest virus
  55.  Other Rickettsias  
  56. Pathogenic Vibrios  Poliovirus (new in FY15)  Powassan/Deer Tick virus  Prions  Protozoa  Rabies virus
  57.  Research on mechanisms of antimicrobial resistance  
  58. Research on therapeutic approaches that target resistance mechanisms  
  59. Ricin toxin (Ricinus communis)  Rubeola (measles) (new in FY14)  Salmonella
  60.  Shigella species  
  61. Siberian subtype  Tuberculosis, including drug-resistant TB  St. Louis encephalitis virus (SLEV)  
  62. Staphylococcus enterotoxin B (SEB)
  63.  Streptococcus, Group A  Studies of the emergence and/or spread of antimicrobial resistance genes within pathogen populations
  64.  Studies of the emergence and/or spread of antimicrobial-resistant pathogens in human populations  
  65.  Respiratory management for the nonintubated COVID-19 patient  
  66. Viral hemorrhagic fevers  Viruses
  67.  West Nile virus (WNV)  
  68. Yersinia enterocolitica  Western equine encephalitis (WEE)  Yellow fever virus (YFV)  
  69. Yersinia pestis (plague)  Zika virus
  70. Typhus fever (Rickettsia prowazekii)  
  71. Clostridium botulinum toxin (botulism)  Coccidioides spp.
  72. Tickborne encephalitis complex flaviviruses  
  73. Rift Valley Fever, Crimean Congo Hemorrhagic Fever  Hepatitis A  Hepatitis C (new in FY14)  
  74. Variola major (smallpox) and other related pox viruses  CDC and ASN issue
  75. Tickborne encephalitis viruses  Tickborne hemorrhagic fever viruses  Toxoplasma gondii
  76. COVID-19 guidelines for care of patients on dialysis
  77.  Venezuelan equine encephalitis (VEE)  

Will be updated soon